KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implants

2023-11-13

Pantheon Vision Established to Develop Novel Innovations to Help Eradicate Corneal Blindness BALTIMORE--(BUSINESS WIRE)-- KeraLink International (KLI) today announced $2.5 million in seed funding in Pantheon Vision (PV) to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs). Pantheon Vision, an early-stage ophthalmic medical device company KLI established, will use the funding to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs. By funding PV, KLI is engaged in a venture philanthropy strategy as part of its PEN approach to eradicating corneal blindness: Prevention of corneal blindness, Early detection and treatment of corneal conditions, and Novel therapies that are effective and affordable for broad use in underserved and under-resourced LMICs. “Development of novel therapeutic solutions is costly but critical to fulfilling our mission of eradicating corneal blindness,” said Douglas J. Furlong, KLI Board Chairman. “We are proud to support Pantheon Vision’s promising work and anticipate a return on this investment that will allow us to fund additional innovative products, technologies, and services.” “Working with generous donors and impact investors, we will fuse the power of market-based solutions with compassionate philanthropy to ensure corneal health in LMICs,” added KLI President and CEO David Green. Ophthalmic industry veteran John Sheets, Ph.D, leads Pantheon Vision. Dr. Sheets has led companies including Hoya and Elisar, and R&D organizations at Alcon, Bausch & Lomb, and Johnson & Johnson. He also served the Food and Drug Administration heading its Office of Device Evaluation. More than 12.7 million children and adults are blind because of corneal injuries or infections, and millions more are blind in one eye or live with seriously impaired vision. KLI is rewriting the narrative of corneal health by advancing ground-breaking products, technologies, and services to eradicate corneal blindness with specific emphasis on low- and middle-income countries. About KeraLink International KeraLink International, Inc. (KLI) is a forward-thinking and innovative non-profit, 501(c)3, driven by empathy and compassion. Fueled by generous support from our donors and investors, KLI is solely focused on eradicating corneal blindness and ensuring the right to sight for people in low- and middle-income countries where corneal blindness persists. We are accelerating a “see change” of innovation by supporting the discovery, development, and deployment of revolutionary yet sustainable and affordable technology solutions to improve corneal health. Learn more at . About Pantheon Vision Pantheon Vision is committed to developing advanced bioengineered solutions to treat corneal blindness better and restore vision for people worldwide. The company seeks to raise the standard of care by improving the patient experience, patient outcomes, and surgical efficiency. The company was formed and initially funded by KeraLink International in furtherance of its mission to eradicate corneal blindness globally, with a focus on LMICs. For more information, visit . View source version on businesswire.com: Contacts Noel S. Selegzi, Director of Development KeraLink International nselegzi@keralink.org Source: KeraLink International View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

KeraLink International, Inc.